RPG Life Sciences Limited Stock

Equities

RPGLIFE

INE105J01010

Pharmaceuticals

Market Closed - NSE India S.E. 09:03:23 2024-04-25 am EDT 5-day change 1st Jan Change
1,549 INR +0.44% Intraday chart for RPG Life Sciences Limited +2.47% +15.94%
Sales 2022 4.4B 52.87M Sales 2023 5.13B 61.6M Capitalization 11.58B 139M
Net income 2022 515M 6.19M Net income 2023 676M 8.12M EV / Sales 2022 1.98 x
Net cash position 2022 560M 6.73M Net cash position 2023 832M 10M EV / Sales 2023 2.1 x
P/E ratio 2022
18 x
P/E ratio 2023
17.1 x
Employees 1,214
Yield 2022
1.71%
Yield 2023
1.71%
Free-Float 29.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.44%
1 week+2.47%
Current month+1.33%
1 month+1.97%
3 months-4.16%
6 months+13.50%
Current year+15.94%
More quotes
1 week
1 499.00
Extreme 1499
1 564.45
1 month
1 458.95
Extreme 1458.95
1 610.00
Current year
1 319.35
Extreme 1319.35
1 740.00
1 year
748.60
Extreme 748.6
1 740.00
3 years
421.80
Extreme 421.8
1 740.00
5 years
142.95
Extreme 142.95
1 740.00
10 years
65.80
Extreme 65.8
1 740.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 15-12-31
Director of Finance/CFO - 20-08-02
Compliance Officer - 11-11-10
Members of the board TitleAgeSince
Chairman 66 08-02-05
Director/Board Member 83 08-02-05
Director/Board Member 60 08-02-05
More insiders
Date Price Change Volume
24-04-25 1,549 +0.44% 5,808
24-04-24 1,542 +0.11% 8,907
24-04-23 1,540 +1.32% 7,758
24-04-22 1,520 +1.92% 6,216
24-04-19 1,492 -1.31% 10,619

Delayed Quote NSE India S.E., April 25, 2024 at 09:03 am EDT

More quotes
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RPGLIFE Stock